Kana Mizuno1, Min Dong1,2, Tsuyoshi Fukuda1,2, Sharat Chandra3,2, Parinda A Mehta3,2, Scott McConnell4, Elias J Anaissie5, Alexander A Vinks6,7. 1. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH, 45229-3039, USA. 2. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. 3. Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 4. Alkermes, Waltham, MA, USA. 5. University of Cincinnati Cancer Institute, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. 6. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH, 45229-3039, USA. Sander.vinks@cchmc.org. 7. Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. Sander.vinks@cchmc.org.
Abstract
BACKGROUND: High-dose melphalan is an important component of conditioning regimens for patients undergoing hematopoietic stem cell transplantation. The current dosing strategy based on body surface area results in a high incidence of oral mucositis and gastrointestinal and liver toxicity. Pharmacokinetically guided dosing will individualize exposure and help minimize overexposure-related toxicity. OBJECTIVE: The purpose of this study was to develop a population pharmacokinetic model and optimal sampling strategy. METHODS: A population pharmacokinetic model was developed with NONMEM using 98 observations collected from 15 adult patients given the standard dose of 140 or 200 mg/m2 by intravenous infusion. The determinant-optimal sampling strategy was explored with PopED software. Individual area under the curve estimates were generated by Bayesian estimation using full and the proposed sparse sampling data. The predictive performance of the optimal sampling strategy was evaluated based on bias and precision estimates. The feasibility of the optimal sampling strategy was tested using pharmacokinetic data from five pediatric patients. RESULTS: A two-compartment model best described the data. The final model included body weight and creatinine clearance as predictors of clearance. The determinant-optimal sampling strategies (and windows) were identified at 0.08 (0.08-0.19), 0.61 (0.33-0.90), 2.0 (1.3-2.7), and 4.0 (3.6-4.0) h post-infusion. An excellent correlation was observed between area under the curve estimates obtained with the full and the proposed four-sample strategy (R 2 = 0.98; p < 0.01) with a mean bias of -2.2% and precision of 9.4%. A similar relationship was observed in children (R 2 = 0.99; p < 0.01). CONCLUSIONS: The developed pharmacokinetic model-based sparse sampling strategy promises to achieve the target area under the curve as part of precision dosing.
BACKGROUND: High-dose melphalan is an important component of conditioning regimens for patients undergoing hematopoietic stem cell transplantation. The current dosing strategy based on body surface area results in a high incidence of oral mucositis and gastrointestinal and liver toxicity. Pharmacokinetically guided dosing will individualize exposure and help minimize overexposure-related toxicity. OBJECTIVE: The purpose of this study was to develop a population pharmacokinetic model and optimal sampling strategy. METHODS: A population pharmacokinetic model was developed with NONMEM using 98 observations collected from 15 adult patients given the standard dose of 140 or 200 mg/m2 by intravenous infusion. The determinant-optimal sampling strategy was explored with PopED software. Individual area under the curve estimates were generated by Bayesian estimation using full and the proposed sparse sampling data. The predictive performance of the optimal sampling strategy was evaluated based on bias and precision estimates. The feasibility of the optimal sampling strategy was tested using pharmacokinetic data from five pediatric patients. RESULTS: A two-compartment model best described the data. The final model included body weight and creatinine clearance as predictors of clearance. The determinant-optimal sampling strategies (and windows) were identified at 0.08 (0.08-0.19), 0.61 (0.33-0.90), 2.0 (1.3-2.7), and 4.0 (3.6-4.0) h post-infusion. An excellent correlation was observed between area under the curve estimates obtained with the full and the proposed four-sample strategy (R 2 = 0.98; p < 0.01) with a mean bias of -2.2% and precision of 9.4%. A similar relationship was observed in children (R 2 = 0.99; p < 0.01). CONCLUSIONS: The developed pharmacokinetic model-based sparse sampling strategy promises to achieve the target area under the curve as part of precision dosing.
Authors: Christa E Nath; Peter J Shaw; Judith Trotman; Lihua Zeng; Stephen B Duffull; Gareth Hegarty; Andrew J McLachlan; Howard Gurney; Ian Kerridge; Yiu Lam Kwan; Peter Presgrave; Campbell Tiley; Douglas Joshua; John Earl Journal: Br J Clin Pharmacol Date: 2010-05 Impact factor: 4.335
Authors: Y K Cho; D W Sborov; M Lamprecht; J Li; J Wang; E M Hade; Y Gao; K Tackett; N Williams; D M Benson; Y A Efebera; A E Rosko; S M Devine; M Poi; C C Hofmeister; M A Phelps Journal: Clin Pharmacol Ther Date: 2017-05-26 Impact factor: 6.875
Authors: Hundie Tesfaye; Romana Branova; Eva Klapkova; Richard Prusa; Daniela Janeckova; Petr Riha; Petr Sedlacek; Petra Keslova; Josef Malis Journal: Ann Transplant Date: 2014-05-09 Impact factor: 1.530
Authors: Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti Journal: Lancet Infect Dis Date: 2014-04-24 Impact factor: 25.071
Authors: Liusheng Huang; Vincent Cheah; Danna Chan; Florence Marzan; Christopher C Dvorak; Francesca T Aweeka; Janel Long-Boyle Journal: Cancer Chemother Pharmacol Date: 2019-02-13 Impact factor: 3.333
Authors: Gunjan L Shah; Jaap Jan Boelens; Dean Carlow; Andrew Lin; Ryan Schofield; Nancy Cruz Sitner; Anna Alperovich; Josel Ruiz; Anthony Proli; Parastoo Dahi; Roni Tamari; Sergio A Giralt; Michael Scordo; Rick Admiraal Journal: Clin Pharmacokinet Date: 2021-12-02 Impact factor: 5.577